Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.
The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38%. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95% reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.
Schwartz
Elissa J
EJ
Division of Nephrology, Mount Sinai Medical Center, New York, NY 10029, USA.
Szczech
Lynda A
LA
Ross
Michael J
MJ
Klotman
Mary E
ME
Winston
Jonathan A
JA
Klotman
Paul E
PE
D016263:AIDS-Associated Nephropathy / Q000175:diagnosis / Q000453:epidemiology* / Q000821:virology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000453:epidemiology; D023241:Antiretroviral Therapy, Highly Active; D044383:Black People; D018450:Disease Progression; D005544:Forecasting; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D016018:Least-Squares Analysis; D008962:Models, Theoretical; D015995:Prevalence; D013997:Time Factors; D014481:United States; D001741:Black or African American